Trial ID 20171 | Maryland Oncology Hematology Trial ID 20171 – Maryland Oncology Hematology

Trial ID 20171

Trial Information - Phase III

ORIENT-15: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Protocol ID: CIBI308A301

Sponsor: Innovent Biologics Ct.

Status: PENDING STAR

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Esophageal

Status

PENDING STAR

Sponsor

Innovent Biologics Ct.

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology